Title:
PHARMACEUTICAL COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL DISORDERS
Document Type and Number:
WIPO Patent Application WO2001041748
Kind Code:
A3
Abstract:
The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity, secretion or abdominal disorders. The dosage is preferably oral. The preferred first agent is tegaserod.
Inventors:
BILLSTEIN STEPHAN ANTHONY (US)
DUMOVIC PETER (US)
FRANCO NICOLA (FR)
IWICKI MARK THOMAS (US)
PFANNKUCHE HANS-JUERGEN (DE)
WILUSZ EDWARD JOSEPH JR (US)
DUMOVIC PETER (US)
FRANCO NICOLA (FR)
IWICKI MARK THOMAS (US)
PFANNKUCHE HANS-JUERGEN (DE)
WILUSZ EDWARD JOSEPH JR (US)
Application Number:
PCT/EP2000/012420
Publication Date:
December 19, 2002
Filing Date:
December 08, 2000
Export Citation:
Assignee:
NOVARTIS AG (CH)
NOVARTIS ERFIND VERWALT GMBH (AT)
BILLSTEIN STEPHAN ANTHONY (US)
DUMOVIC PETER (US)
FRANCO NICOLA (FR)
IWICKI MARK THOMAS (US)
PFANNKUCHE HANS-JUERGEN (DE)
WILUSZ EDWARD JOSEPH JR (US)
NOVARTIS ERFIND VERWALT GMBH (AT)
BILLSTEIN STEPHAN ANTHONY (US)
DUMOVIC PETER (US)
FRANCO NICOLA (FR)
IWICKI MARK THOMAS (US)
PFANNKUCHE HANS-JUERGEN (DE)
WILUSZ EDWARD JOSEPH JR (US)
International Classes:
A61K31/135; A61K31/138; A61K31/195; A61K31/197; A61K31/341; A61K31/404; A61K31/4045; A61K31/4439; A61K31/451; A61K31/485; A61K45/06; A61P1/00; A61P1/04; A61P1/08; A61P1/10; A61P1/12; A61P1/14; (IPC1-7): A61K31/4045; A61K31/138; A61K31/195; A61P1/00; A61K31/135
Domestic Patent References:
| WO1999017755A2 | 1999-04-15 | |||
| WO1994001095A2 | 1994-01-20 | |||
| WO1993012785A1 | 1993-07-08 |
Foreign References:
| EP0505322A1 | 1992-09-23 |
Other References:
SCOTT & PERRY: "TEGASEROD", DRUGS,AT,ADIS INTERNATIONAL LTD, vol. 58, no. 3, 1999, pages 492 - 496, XP000874675, ISSN: 0012-6667
STEADMAN C J ET AL: "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study", MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, US, vol. 67, no. 8, August 1992 (1992-08-01), pages 732 - 738, XP002098638, ISSN: 0025-6196
STEADMAN C J ET AL: "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study", MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, US, vol. 67, no. 8, August 1992 (1992-08-01), pages 732 - 738, XP002098638, ISSN: 0025-6196
Download PDF: